{"fetched":"2026-10-21","register":{"rows":2754,"human":2357,"radiopharmaceutical":44,"generatedOn":"2026-10-21"},"verified":[{"drugId":"radium-223","region":"EU","status":"approved","year":2013,"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/xofigo","verifiedOn":"2026-10-21"},{"drugId":"ga-68-dotatoc","region":"EU","status":"approved","year":2016,"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/somakit-toc","verifiedOn":"2026-10-21"},{"drugId":"lutathera","region":"EU","status":"approved","year":2017,"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/lutathera","verifiedOn":"2026-10-21"},{"drugId":"f-18-florbetaben","region":"EU","status":"approved","year":2014,"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/neuraceq","verifiedOn":"2026-10-21"},{"drugId":"pluvicto","region":"EU","status":"approved","year":2022,"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto","verifiedOn":"2026-10-21"},{"drugId":"ga68-psma-11","region":"EU","status":"approved","year":2022,"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/locametz","verifiedOn":"2026-10-21"},{"drugId":"fluciclovine-f18","region":"EU","status":"approved","year":2017,"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/axumin","verifiedOn":"2026-10-21"},{"drugId":"f-18-flutemetamol","region":"EU","status":"approved","year":2014,"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/vizamyl","verifiedOn":"2026-10-21"},{"drugId":"i-123-ioflupane","region":"EU","status":"approved","year":2000,"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/datscan","verifiedOn":"2026-10-21"},{"drugId":"f-18-flortaucipir","region":"EU","status":"approved","year":2024,"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/tauvid","verifiedOn":"2026-10-21"},{"drugId":"f-18-florbetapir","region":"EU","status":"approved","year":2013,"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/amyvid","verifiedOn":"2026-10-21"},{"drugId":"samarium-153-lexidronam","region":"EU","status":"approved","year":1998,"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/quadramet","verifiedOn":"2026-10-21"},{"drugId":"tilmanocept-tc99m","region":"EU","status":"withdrawn","year":2024,"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/lymphoseek","verifiedOn":"2026-10-21"}],"candidates":[{"region":"EU","product":"Ilumira","inn":"lutetium (177Lu) chloride","reason":"not-in-corpus","register":"Authorised","date":"2026-03-26","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/ilumira","indication":"Ilumira is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177Lu) chloride."},{"region":"EU","product":"GalenVita","inn":"germanium (68Ge) chloride;gallium (68Ga) chloride","reason":"not-in-corpus","register":"Authorised","date":"2026-01-08","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/galenvita","indication":"This radionuclide generator is not intended for direct use in patients. The sterile eluate (gallium (68Ga) chloride solution) from the radionuclide generator GalenVita is indicated for in vitro radiolabelling of various kits for radiopharmaceutical preparation developed and approved for radiola"},{"region":"EU","product":"Theralugand","inn":"lutetium (177Lu) chloride","reason":"not-in-corpus","register":"Authorised","date":"2024-11-22","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/theralugand","indication":"Theralugand is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177Lu) chloride."},{"region":"EU","product":"GalliaPharm","inn":"gallium (68Ga) chloride;germanium (68Ge) chloride","reason":"not-in-corpus","register":"Authorised","date":"2024-08-01","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/galliapharm","indication":"This radionuclide generator is not intended for direct use in patients. The sterile eluate (gallium (68Ga) chloride solution) from the radionuclide generator GalliaPharm is indicated for in vitro radiolabelling of various kits for radiopharmaceutical preparation developed and approved for radiolabel"},{"region":"EU","product":"Pylclari","inn":"piflufolastat (18F)","reason":"not-in-corpus","register":"Authorised","date":"2023-11-27","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/pylclari","indication":"This medicinal product is for diagnostic use only. Pylclari is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:  Primary staging of patients with "},{"region":"EU","product":"Lutetium (177Lu) chloride Billev (previously Illuzyce)","inn":"lutetium (177Lu) chloride","reason":"not-in-corpus","register":"Authorised","date":"2022-09-15","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/lutetium-177lu-chloride-billev","indication":"Lutetium (177Lu) chloride Billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177Lu) chloride."},{"region":"EU","product":"LysaKare","inn":"arginine;lysine","reason":"not-in-corpus","register":"Authorised","date":"2019-07-25","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/lysakare","indication":"LysaKare is indicated for reduction of renal radiation exposure during Peptide-Receptor Radionuclide Therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults."},{"region":"EU","product":"EndolucinBeta","inn":"lutetium (177Lu) chloride","reason":"not-in-corpus","register":"Authorised","date":"2016-07-06","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/endolucinbeta","indication":"EndolucinBeta is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with Lutetium (177Lu) chloride."},{"region":"EU","product":"Cuprymina","inn":"copper (64Cu) chloride","reason":"not-in-corpus","register":"Authorised","date":"2012-08-23","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/cuprymina","indication":"Cuprymina is a radiopharmaceutical precursor. It is not intended for direct use in patients. This medicinal product must be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide."},{"region":"EU","product":"Rapiscan","inn":"regadenoson","reason":"not-in-corpus","register":"Authorised","date":"2010-09-06","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/rapiscan","indication":"This medicinal product is for diagnostic use only. Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress."},{"region":"EU","product":"Scintimun","inn":"besilesomab","reason":"not-in-corpus","register":"Authorised","date":"2010-01-11","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/scintimun","indication":"This medicinal product is for diagnostic use only and the approved indication is scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis. Scintimun should not be "},{"region":"EU","product":"Yttriga","inn":"yttrium [90Y] chloride","reason":"not-in-corpus","register":"Authorised","date":"2006-01-19","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/yttriga","indication":"To be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.Radiopharmaceutical precursor - Not intended for direct use in patients."}],"errors":[],"sources":{"ema":"https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx","mhra":{"url":"https://products.mhra.gov.uk/","note":"MHRA's products site has no documented public API; UK rows stay hand-verified against the SmPC search."},"pmda":{"url":"https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html","note":"PMDA publishes its list of approved products as PDF only; Japanese rows stay hand-verified."}}}